Bryson Katona is a Gastroenterology physician affiliated with Penn Center for AIDS Research. OpenAlex indexes 300 publications with 4,451 citations (h-index 34); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
Sponsor: Abramson Cancer Center at Penn Medicine
- Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
Sponsor: Abramson Cancer Center at Penn Medicine
- CTNNA1 Familial Expansion Study
Sponsor: Abramson Cancer Center at Penn Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
54.2%Proton pump inhibitor54.2%Omeprazole100%Part D<11 patientsMusculoskeletal
45.8%Nonsteroidal Anti-inflammatory Drug45.8%Sulindac100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2015–2024 per NIH RePORTER. The latest:
- Defining the phenotype and cancer penetrance of CTNNA1 loss-of-function germline variants
University of Pennsylvania
FY2024$221,621R21CA267949 - Defining the phenotype and cancer penetrance of CTNNA1 loss-of-function germline variants
University of Pennsylvania
FY2023$195,301R21CA267949 - Menin regulates colonic epithelial cell growth through LXR repression
University of Pennsylvania
FY2020$121,500R03DK120946
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Charu Aggarwal, MD, MPH
Penn Center for AIDS Research
Janos Tanyi, MD
Penn Center for AIDS Research
Daniel Landsburg, MD
Penn Center for AIDS Research
Meera Harhay, MD
Penn Center for AIDS Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”